A Remote, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine Transdermal System in Adolescent Subjects With Idiopathic Restless Legs Syndrome
Phase of Trial: Phase III
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Rotigotine (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 18 Jan 2019 Status changed from not yet recruiting to recruiting.
- 19 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.
- 08 Nov 2018 New trial record